Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
During the last three months, 4 analysts shared their evaluations of Revvity (NYSE:RVTY), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 2 | 1 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 0 | 0 | 0 | 0 | 0 |
3M Ago | 0 | 2 | 1 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $123.25, along with a high estimate of $130.00 and a low estimate of $110.00. Witnessing a positive shift, the current average has risen by 13.59% from the previous average price target of $108.50.
The perception of Revvity by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Dan Brennan | TD Cowen | Raises | Buy | $130.00 | $123.00 |
Daniel Arias | Stifel | Raises | Hold | $110.00 | $95.00 |
Paul Knight | Keybanc | Raises | Overweight | $126.00 | $110.00 |
Andrew Cooper | Raymond James | Raises | Outperform | $127.00 | $106.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Revvity's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Revvity analyst ratings.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Revvity faced challenges, resulting in a decline of approximately -6.11% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Revvity's net margin is impressive, surpassing industry averages. With a net margin of 11.29%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Revvity's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.01%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Revvity's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.58%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.52, Revvity adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RVTY